Deucravacitinib in dermatology: current indication and existing off-label data
Tyrosine kinase 2 (TYK2) inhibition has recently emerged as a novel therapeutic strategy in dermatology, targeting key cytokine pathways involved in immune-mediated inflammatory diseases. Deucravacitinib, an oral, selective TYK2 inhibitor that binds the regulatory pseudokinase domain, modulates sign...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioExcel Publishing Ltd
2026-06-01
|
| Serier: | Drugs in Context |
| Fag: | |
| Online adgang: | https://www.drugsincontext.com/deucravacitinib-in-dermatology-current-indication-and-existing-off-label-data/ |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|